It’s unlikely a lipid-lowering agent can directly reduce infection or malignancy, but some argue it could stop a domino ...

Multiple US health systems have been awaiting the authorization before taking the Queen of Hearts platform live.

Mirvat Alasnag talks with host Yael L. Maxwell about the need to prove herself, social media, and partnerships with patients.

Doing TAVI first was noninferior to a PCI-first strategy, with experts pointing out that each timing has its advantages.

Novartis announced that the phase III CV outcomes trial did not meet its primary endpoint, raising doubts over Lp(a)’s role.

It’s unclear if individual parts of the intervention or the integrated approach itself contributed to improvement over usual ...

While there was no change in disability-free survival, the results should impact guidelines, says François Mach.

The phase II trial didn’t look at MACE, but excitement over inflammation’s role in CVD—and how to tame it—isn’t done yet.

SWITCH-SWEDEHEART’s unique design randomized healthcare regions but wasn’t a head-to-head comparison with ticagrelor.

Among patients with nonobstructive hypertrophic cardiomyopathy (HCM), the selective cardiac myosin inhibitor aficamten ...

While no comparable guidelines exist in the US, Richard Kovacs of the ACC said he considers it to be “eye-opening.” ...

The lack of impact on outcomes was surprising, says the investigator, though the FAST-CTCA trial may still come through.